Educational Needs & Objectives
June 1 – June 2, 2018
InterContinental New York Times Square
New York, New York
This course will address 3 broad areas — maximizing the role of Advanced Practice Providers in urology practice, establishing subspecialty clinics( advanced cancer clinics, women’s health clinics, and men’s health clinics), and new biomarkers in uro-oncology.
Scope of practice and correct billing practices of Advanced Practice Providers are widely misunderstood nationwide. With Urology being one of the top two shortage specialties, it is imperative that we further the understanding of the role an APP can provide as well as the proper regulatory methods for these activities.
A recent survey published by the NCBI indicated that 36% of patients that were treated by the urologists participating in the study had cancer, and of those patients 64% had prostate cancer. Given the expanding treatment options for treating the patient with CRPC it is a critical time for urologists to seriously consider establishing a clinic in order to provide more continuous care to these patients. Continuous care has proven to be beneficial for the patient, especially in a multidisciplinary clinic. This approach may be increasingly useful as prostate cancer patients now face a complex array of treatment options, including different surgical methods, radiation therapies, and active surveillance. Similarly, there are multiple new therapies for treatment of bladder cancer which promises to shift care of that disease in the same direction. This educational series is designed specifically for individuals who want to establish an advanced cancer clinic, or for those who are currently considering a clinic and wish to better understand the associated costs and benefits.
Over the past five years there has been a flood of new biomarkers approved by the FDA for the diagnosis and treatment of urologic malignancies. This number is now over ten. Providers in urology have been overwhelmed by keeping up with daily practice while at the same time learning how to appropriately employ these tests in practice. These meetings will provide the foundation needed to accomplish that goal.
Overall Educational Objectives
- Apply the key elements necessary to establish a business plan in the clinical practice setting to effectively maximize utility of Advanced Practice Providers.
- Apply clinical and management of advanced urologic malignancies for the community practice setting.
- Explain AUA and NCCN Guidelines for FDA approved agents and tests in the management of urologic malignancies for patient clinical benefit.
- Evaluate uncommon signs and symptoms a patient may present in challenging cases and gain a better understanding from the patient perspective.